论文部分内容阅读
目的:评估米非司酮治疗多囊卵巢综合症100例临床效果。方法:通过选取100例多囊卵巢综合症患者,平均分为两组,米非司酮治疗观察组和普通治疗对照组,用药时间为12个研究周期,比较两组促黄体生成素(LH)、促卵泡生产素(FSH)、LH/FSH水平、受孕率、排卵率和总有效率。结果:经过治疗的两组患者降低LH、FSH水平、提高受孕率、排卵率和总有效率,观察组显著高于对照组,差异具有统计学意义(P<0.05)。结论:米司非酮的临床应用范围进一步扩大,能够显著降低多囊卵巢综合症患者的LH、LH/FSH水平,提高受孕率、排卵率,改善治疗效果。
Objective: To evaluate the clinical efficacy of mifepristone in the treatment of 100 cases of polycystic ovary syndrome. Methods: 100 patients with PCOS were selected and divided into two groups equally. The patients in the mifepristone treatment group and the normal control group were treated with 12 study periods. Luteinizing hormone (LH) Follicle-stimulating hormone (FSH), LH / FSH level, conception rate, ovulation rate and total effective rate. Results: After treatment, the two groups of patients reduced LH and FSH levels, increased the pregnancy rate, ovulation rate and total effective rate. The observation group was significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical application scope of mifepristone is further expanded, which can significantly reduce the levels of LH and LH / FSH in polycystic ovary syndrome patients and improve the pregnancy rate and ovulation rate and improve the therapeutic effect.